玻璃体腔注射Pegcetacoplan治疗地图样萎缩的两年临床实践
本回顾性介入病例系列纳入58例患者的77只眼,接受15mg玻璃体腔注射Pegcetacoplan治疗地图样萎缩并完成2年随访。在72只有可测量病灶的眼中有49只眼有治疗前年度随访数据,其病灶平方根增长速率由治疗前0.33±0.21 mm/年降至2年后0.19±0.11 mm/年,降幅41%(p < .001);平均BCVA由63±14个字母降至55±16个字母(p < .001)。
要点
- Pegcetacoplan治疗2年使地图样萎缩平方根增长速率降低约41%。
- 第二年的疗效继续累积,72只眼中71只增长速率下降或持平。
- 治疗前增长速率越快,治疗后的增长抑制百分比越高。
核心结论
- Pegcetacoplan治疗2年使地图样萎缩增长速率降低约41%,并在第二年继续显示累积疗效。
研究设计与样本
- 回顾性介入病例系列,纳入继发于AMD的症状性地图样萎缩眼,接受15mg玻璃体腔注射Pegcetacoplan并参与正在进行的SS-OCTA影像研究。
- 2023年4月12日至2025年12月8日期间,58例患者的77只眼继续治疗2年,平均接受18±3次注射,注射间隔1.3个月。
主要发现
- 72只有2年随访且地图样萎缩可测量的眼,治疗后平方根增长速率为0.22±0.12 mm/年。
- 72只眼中71只第二年平方根增长速率进一步下降或保持不变,1只因渗出性MNV同时接受抗VEGF治疗而增长速率增加。
- 72只眼中49只有治疗前年度随访,其平方根增长速率由治疗前0.33±0.21 mm/年降至2年后0.19±0.11 mm/年,降幅41%(p < .001)。
- 中心凹与非中心凹地图样萎缩的增长速率无显著差异(所有p ≥ .99)。
- 平均BCVA由63±14个字母降至55±16个字母(p < .001),中心凹与非中心凹地图样萎缩间无显著差异(p = .14)。
临床怎么用
- 对于继发于AMD的症状性地图样萎缩,可考虑玻璃体腔注射Pegcetacoplan 15mg以减缓病灶增长。
- 治疗前增长速率较快的病灶可能从治疗中获得更大的增长抑制百分比。
局限性
- 为回顾性介入病例系列,非随机对照设计。
- 样本来自单中心接受SS-OCTA影像研究的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the 2-year experience of using intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) in age-related macular degeneration (AMD). DESIGN: Retrospective interventional case series. METHODS: Eyes with symptomatic GA secondary to AMD were treated with 15mg of intravitreal pegcetacoplan and participated in an ongoing prospective swept-source optical coherence tomography angiography (SS-OCTA) imaging study. All eyes underwent SS-OCTA imaging before and during pegcetacoplan therapy to assess for GA lesion size, the presence of non-exudative macular neovascularization (MNV), and the onset of exudation. The growth rate of GA and best-corrected visual acuity (BCVA) were assessed for all eyes treated for 2 years. RESULTS: From April 12, 2023 to December 8, 2025, 77 eyes from 58 patients continued pegcetacoplan treatment for 2 years. Eyes received an average of 18 ± 3 injections with an interval of 1.3 months between injections. For the 72 eyes with 2 years of follow-up and measurable GA, the square-root (sqrt) GA growth rate after pegcetacoplan treatment was 0.22 ± 0.12 mm/year. Of the 72 eyes, 71 eyes either decreased further in their sqrt GA growth rate or remained the same in the second year, while 1 eye had an increase in the sqrt GA growth rate. This eye also received concomitant anti-VEGF therapy due to exudative MNV. Of these 72 eyes, 49 eyes had prior annual visits before treatment. In these eyes, the annual sqrt GA growth rate was 0.33 ± 0.21 mm/year before pegcetacoplan and 0.19 ± 0.11 mm/year after 2 years, resulting in a 41% decrease in the growth rate (p < .001). There were no significant differences in GA growth rates between foveal and non-foveal GA (all p ≥ .99). The mean BCVA declined from 63 ± 14 to 55 ± 16 letters over 2 years (p < .001), with no significant difference between foveal and non-foveal GA (p = .14). Positive correlations were found between the sqrt GA growth rates prior to treatment and the percent growth inhibition over both 1 year (r = 0.33, p = .02) and 2 years of treatment (r = 0.40, p = .007). CONCLUSIONS: Pegcetacoplan therapy reduced the growth rate of GA by about 41% over 2 years and continued to show accumulated efficacy during the second year.
引用
- Shen M, Lam WZ, Berni A, et al. Two-Year Experience With Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Clinical Practice. Am J Ophthalmol. 2026. PMID: 42727684. doi:10.1016/j.ajo.2026.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。